The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...

Shares of ZLAB opened at $35.39 on Tuesday. Zai Lab has a one year low of $13.48 and a one year high of $36.60. The stock has a 50-day moving average price of $28.10 and a 200 day moving average ...